Notably, MDSCs in the glioma TME express the IL-15 receptor, CAR-T cells engineered to express IL-15 create a dual-targeting system that reduces the presence of both MDSCs and glioma cells while reversing the immunosuppressive effects of MDSCs in laboratory settings (157). The gene discussed is IL15; the disease is central nervous system cancer.